Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
暂无分享,去创建一个
B. Monk | R. Coleman | C. Aghajanian | J. Schilder | G. Sutton | Joan L. Walker | K. Tewari | M. Sill | C. Darus | J. Balkissoon | Lainie P Martin
[1] E. Kohn,et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. , 2014, The Lancet. Oncology.
[2] R. Mason,et al. Dynamic contrast enhanced fluorescent molecular imaging of vascular disruption induced by combretastatin-A4P in tumor xenografts. , 2014, Journal of biomedical nanotechnology.
[3] A. Reuss,et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Eskander,et al. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications. , 2014, Gynecologic oncology.
[5] Kiran Gurung,et al. Mechanisms of tumor resistance to small-molecule vascular disrupting agents: treatment and rationale of combination therapy. , 2013, Journal of the Formosan Medical Association = Taiwan yi zhi.
[6] M. Mita,et al. Vascular-disrupting agents in oncology , 2013, Expert opinion on investigational drugs.
[7] L. Peshkin,et al. Vascular Disrupting Agent Drug Classes Differ in Effects on the Cytoskeleton , 2012, PloS one.
[8] A. Harris,et al. Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer , 2012, Clinical Cancer Research.
[9] M. Parmar,et al. Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) , 2010, International Journal of Gynecologic Cancer.
[10] Michael W Sill,et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] B. Turnbull,et al. Group Sequential Methods with Applications to Clinical Trials , 1999 .
[12] J. O'fallon,et al. Stopping when the experimental regimen does not appear to help. , 1994, Statistics in medicine.
[13] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.